Edgardo G. Bottaro

B, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: June 16, 2026

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations.

Journal: AIDS (London, England)

Published: March 14, 2026

Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease.

Bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in advanced HIV disease.

Journal: Medicina

Published: October 18, 2025

Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice.

Effectiveness and safety of dual therapy with co-packaged dolutegravir and lamivudine compared to triple therapy as switching strategy in clinical practice.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: June 16, 2025

Clinical and epidemiological characteristics of the 2022-2023 Mpox outbreak in Buenos Aires, Argentina.

Clinical and epidemiological characteristics of the 2022-2023 Mpox outbreak in Buenos Aires, Argentina.

Journal: Medicina

Published: February 03, 2025

Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort.

Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort.

Journal: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

Published: November 20, 2024

Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina.

Telemedicine in HIV health care during the COVID-19 pandemic: An implementation research study in Buenos Aires, Argentina.

Journal: HIV medicine

Published: November 13, 2023

Impact of COVID-19 related lockdown on the metabolic profile of people with HIV infection in Argentina

Impact of COVID-19 related lockdown on the metabolic profile of people with HIV infection in Argentina

Journal: Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia

Published: September 20, 2021

Candidemia subsequent to Clostridium difficile infection: direct relationship or coincidence?

Candidemia subsequent to Clostridium difficile infection: direct relationship or coincidence?

Journal: Enfermedades infecciosas y microbiologia clinica

Published: June 19, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026